

INSTRUCTIONS:

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form has five parts.

1. Identifying information.

Each author should submit a separate form. Provide complete information and double-check the manuscript number. If you are NOT the corresponding author please insert his or her name.

2. The work under consideration for publication.

Please provide information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The idea is to provide for the reader information about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. If you check the "No" box it means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds to pay you. If you or your institution did receive funds from a third party to support the work, check "Yes" along with the appropriate boxes to indicate the type of support and whether you or your institution received it.

3. Relevant financial activities outside the submitted work.

Please report all sources of revenue relevant to the submitted work that accrued either directly to you or were paid to your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. If there is any question, it is usually better to disclose a relationship than not to do so. Please note that your interactions with the work's sponsor outside the submitted work should be listed here. For each category list each entity on a separate line. Use as many lines as necessary to provide complete information. In addition, please disclose relationships that fall outside the 36-month window that readers may want to know about and could reasonably criticize you for not disclosing (for example, long-term financial relationships that are now ended).

The goal of this section is to provide information for our reviewers and readers about your interactions with entities in the biomedical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer. For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to benefit financially from the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as the NIH or the MRC, need not be disclosed. For example, if the NIH sponsored a piece of work you have been involved in but drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Financial relationships involving your spouse or partner or your children (under 18 years of age).

If monies from the types of relationships listed in Section 3 were paid to your spouse or partner or dependent children, please list the type of activity and source of the money.

5. Nonfinancial associations.

Please report any personal, professional, political, institutional, religious, or other associations that a reasonable reader would want to know about in relation to the submitted work.



Section 1. Identifying Information.

| Given Name: (or first) | John | Surname: (or last) | Buse | Effective Date: | 05-August-2010 | | | | |
|--|--|-----------------------|------|-----------------|---------------------|--|--|--|--|
| | corresponding author? [| | lo | Format examp | ple: 07-August-2008 | | | | |
| Manuscript Ti | Manuscript Title: Exenatide BID Use in Insulin-Treated Type 2 Diabetes: A Randomized, Controlled Trial | | | | | | | | |
| Manuscript Identifying Number (if you know it): M10-1795 | | | | | | | | | |

Section 2. Information about the support of the work under consideration for publication.

Did you or your institution at any time receive payment or support in kind for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

🗌 No

Yes, specify nature of compensation

If you have more than one relationship, click "Add +" to add a row. Click "Del ×" to delete an extra row.

| Туре | | Money Paid to You* Money to Your Institution | | bur | Name of Entity | Comments** | |
|--|-------------|--|-------------|-----------|----------------|---|---------------------|
| | No | Yes | No | Yes | | | |
| Grant | \square | | | \square | Lilly | For clinical trial | $\text{Del} \times$ |
| | | | | | | | Add + |
| Consulting fee or honorarium | | | | \square | Lilly | Consulting | Del × |
| | | | | | | | Add + |
| Support for travel to meetings for the study or otherwise | | \square | | | Lilly | Likely has reimbursed expenses at some point in time for travel but I have no record of that. | Del × |
| | | | | | · | | Add + |
| Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like | \boxtimes | | \boxtimes | | | | Del × |
| | | | | | | | Add + |
| Payment for writing or reviewing the manuscript | | | | | | | Del × |
| | | | | | | | Add + |



| Туре | | y Paid 'ou* | Yo | ey to our ution | Name of Entity | Comments** | |
|--|-----------|----------------|-------------|-----------------------|----------------|--------------------|-------|
| Support in kind such as writing, provision of medicines or equipment, or administrative support | | | | \boxtimes | Lilly | For clinical trial | Del × |
| | | | | | • | | Add + |
| Other | \square | | \boxtimes | | | | Del × |
| | | | 1 | | | | Add + |

**Use this section to provide any needed explanation

Section 3. Information about relevant financial relationships outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with any entities that have an interest related to the submitted work. Use one line for each entity; add as many lines as you need. Use the comments column to indicate any additional information that you think a reader or editor would want to know about the compensation. Report relationships that were present during the 36 months prior to submission. In addition please disclose relationships that fall outside the 36-month window that readers may want to know about and could reasonably criticize you for not disclosing (for example, long-term financial relationships that are now ended).

If you have more than one relationship, click "Add +" to add a row. Click "Del ×" to delete an extra row.

| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your institution | Entity | Comments | |
|---|-------------|-------------------------|---------------------------------|----------------------|------------------|---------------------|
| Board membership | \boxtimes | | | | | $\text{Del} \times$ |
| | | I | I | | 1 | Add + |
| Consultancy | | | \square | Becton-Dickinson | | $\text{Del} \times$ |
| Consultancy | | | \square | Lilly | | Del × |
| Consultancy | | | \square | Hoffman LaRoche | (now, Genentech) | Del × |
| Consultancy | | | \square | GlycoMark | | Del × |
| Consultancy | | | \square | Wyeth | | Del × |
| Consultancy | | | \square | Daichi Sankyo | | Del × |
| Consultancy | | | \square | Bristol-Myers Squibb | | Del × |
| Consultancy | | | \square | Bayhill Therapeutics | | Del × |
| Consultancy | | | \square | LipoScience | | Del × |
| Consultancy | | | \square | MannKind | | Del × |
| Consultancy | | | \boxtimes | Veritas | | $\text{Del} \times$ |



| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your institution | Entity | Comments | |
|---|-------------|-------------------------|---------------------------------|-------------------------------|-----------------|--------------|
| Consultancy | | | \square | MicroIslet | | Del × |
| Consultancy | | | \square | GlaxoSmithKline | | Del × |
| Consultancy | | | \square | Abbott | | Del × |
| Consultancy | | | \square | Exsulin | | Del × |
| Consultancy | | | \square | GI Dynamics | | Del × |
| Consultancy | | | \square | Spherix | | Del × |
| Consultancy | | | \square | Amylin | | Del × |
| | | | • | | | Add + |
| Employment | | \boxtimes | | UNC School of Medicine | | $Del \times$ |
| | | | | | | Add + |
| Expert testimony | | | \boxtimes | Novo Nordisk | | $Del \times$ |
| | | | | | | Add + |
| Gifts | \boxtimes | | | | | Del × |
| | | | | | | Add + |
| Grants/grants pending | | | \square | Amylin | | Del × |
| Grants/grants pending | | | \square | Novo Nordisk | | Del × |
| Grants/grants pending | | | \square | Medtronic | | Del × |
| Grants/grants pending | | | \boxtimes | Lilly | | $Del \times$ |
| Grants/grants pending | | | \boxtimes | Novartis | | $Del \times$ |
| Grants/grants pending | | | \boxtimes | Tolerex | | $Del \times$ |
| Grants/grants pending | | | \boxtimes | Osiris | | $Del \times$ |
| Grants/grants pending | | | \boxtimes | Halozyme | | $Del \times$ |
| Grants/grants pending | | | \boxtimes | Pfizer | | $Del \times$ |
| Grants/grants pending | | | \boxtimes | Hoffman LaRoche | (now Genentech) | $Del \times$ |
| Grants/grants pending | | | \boxtimes | Interkrin | | $Del \times$ |
| Grants/grants pending | | | \boxtimes | Merck | | $Del \times$ |
| Grants/grants pending | | | \square | sanofi-aventis | | Del × |
| Grants/grants pending | | | \square | Dexcom | | Del × |
| Grants/grants pending | | | \square | Johnson & Johnson | | Del × |
| Grants/grants pending | | | \square | National Institutes of Health | | Del × |
| Grants/grants pending | | | \square | Bristol-Myers Squibb | | $Del \times$ |



| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your institution | Entity | Comments | |
|--|-------------|-------------------------|---------------------------------|---|---|---------------------|
| Grants/grants pending | | | | Fujisawa | | Del × |
| Grants/grants pending | | | | American Academy of Family Practice Foundation | | Del × |
| Grants/grants pending | | | \square | National Institutes of Health | | Del × |
| Grants/grants pending | | | \square | Novartis | | Del × |
| | | | | | | Add + |
| Honoraria | \boxtimes | | | | | $\text{Del} \times$ |
| | | | , | | | Add + |
| Payment for manuscript preparation | \boxtimes | | | | | Del× |
| | | | | | | Add + |
| Patents (planned, pending or issued) | \boxtimes | | | | | $\text{Del} \times$ |
| | | 1 | | | I | Add + |
| Royalties | \boxtimes | | | | | Del × |
| | | I | I | 1 | 1 | Add + |
| Payment for development of educational presentations including service on speakers' bureaus | | | | | | Del × |
| | | 1 | | | I | Add + |
| Stock/stock options | | \square | | Insulet | | Del × |
| | | • | • | | | Add + |
| Travel/accommodations expenses covered or reimbursed | | | | All of the above in the context of University contracted activities | I suspect that I have been reimbursed for travel related expenses by the above named companies at some time related to my University work, but I do not keep documentation. | Del × |
| Travel/accommodations expenses covered or reimbursed | | | | American Diabetes Association | | Del × |
| | | | | | | Add + |
| Other (err on the side of full disclosure) | \boxtimes | | | | | Del × |
| | | | | | | Add + |



Section 4. Information about financial relationships involving your spouse or partner or your children (under 18 years of age).

Do your children or your spouse or partner have financial relationships with entities that have an interest in the content of the submitted work?

No other relationships/conditions/circumstances that present potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

Section 5. Information about relevant nonfinancial associations.

Do you have any relevant nonfinancial associations or interests (personal, professional, political, institutional, religious, or other) that a reasonable reader would want to know about in relation to the submitted work?

No relevant nonfinancial relationships/conditions/circumstances to report.

Yes, the following relevant nonfinancial relationships/conditions/circumstances are present (explain below):

l am or have been a member of a variety of non-profit boards: American Diabetes Association, DiabetesSisters, Taking Control of Your Diabetes

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Save Form



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



| Section 1. | Identifying Inform | mation | | |
|---|--------------------|------------------------------------|--|--|
| 1. Given Name (Fi Cory | rst Name) | 2. Surname (Last Name) Heilmann | | 3. Effective Date (07-August-2008) 24-August-2010 |
| 4. Are you the corresponding author? | | Yes 🖌 No | Corresponding Author's Na John Buse | me |
| 5. Manuscript Title Exenatide BID Us | | ype 2 Diabetes: A Random | nized, Controlled Trial | |

6. Manuscript Identifying Number (if you know it)

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

| The Work Under Consideration for Publication | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | |
| 1. Grant | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 2. Consulting fee or honorarium | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 3. Support for travel to meetings for the study or other purposes | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 5. Payment for writing or reviewing the manuscript | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| Provision of writing assistance, medicines, equipment, or administrative support | \checkmark | | | | | × | | |



| The Work Under Consideration for Publication | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | |
| | | | | | | ADD | | |
| 7. Other | \checkmark | | | | | × | | |
| | | | | | | ADD | | |

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

| Relevant financial activities outside the submitted work | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|-----------|----------------------------------|-----|--|--|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | | | |
| 1. Board membership | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 2. Consultancy | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 3. Employment | | \checkmark | | Eli Lilly | l am an employee of Eli Lilly | × | | |
| | | | | | | ADD | | |
| 4. Expert testimony | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 5. Grants/grants pending | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| Payment for lectures including service on speakers bureaus | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 7. Payment for manuscript preparation | \checkmark | | | | | × | | |



| Relevant financial activities outside the submitted work | | | | | | | |
|--|--------------|-------------------------|----------------------------------|-----------|--|-----|--|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | | |
| | | | | | | ADD | |
| 8. Patents (planned, pending or issued) | \checkmark | | | | | × | |
| | | | | | | ADD | |
| 9. Royalties | \checkmark | | | | | × | |
| | | | | | | ADD | |
| 10. Payment for development of educational presentations | \checkmark | | | | | × | |
| | | | | | | ADD | |
| 11. Stock/stock options | | \checkmark | | Eli Lilly | l am a shareholder of Eli Lilly | × | |
| | | | | | | ADD | |
| Travel/accommodations/ meeting expenses unrelated to activities listed** | | \checkmark | | Eli Lilly | Eli Lilly supports my travel to meetings such as the ADA | × | |
| | | | | | | ADD | |
| 13. Other (err on the side of full disclosure) | \checkmark | | | | | × | |
| | | | | | | ADD | |

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section 4.

Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'





Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



| Section 1. | Identifying Inform | ation | | | | | | |
|--|----------------------------|--------------------|----------------|--|--|--|--|--|
| 1. Given Name (Fin Leonard | rst Name) | 2. Surnar Glass | ne (Last Name) | | 3. Effective Date (07-August-2008) 26-August-2010 | | | |
| 4. Are you the cor | responding author? | Yes | ✓ No | Corresponding Author's Na John Buse, MD | ame | | | |
| 5. Manuscript Title Exenatide BID Use in Insulin-Treated Type 2 Diabetes: A Randomized, Controlled Trial. | | | | | | | | |
| 6. Manuscript Ider | ntifying Number (if you kn | iow it) | | | | | | |

M10-1795

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

| The Work Under Consideration for Publication | | | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | | | |
| 1. Grant | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| 2. Consulting fee or honorarium | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| 3. Support for travel to meetings for the study or other purposes | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| 5. Payment for writing or reviewing the manuscript | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| Provision of writing assistance, medicines, equipment, or administrative support | \checkmark | | | | | × | | | | |



| The Work Under Consideration for Publication | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | |
| | | | | | | ADD | | |
| 7. Other | \checkmark | | | | | × | | |
| | | | | | | ADD | | |

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

| Relevant financial activities outside the submitted work | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|-----------------------|----------|-----|--|--|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | | | |
| 1. Board membership | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 2. Consultancy | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 3. Employment | | \checkmark | | Eli Lilly and Company | | × | | |
| | | | | | | ADD | | |
| 4. Expert testimony | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| 5. Grants/grants pending | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| Payment for lectures including service on speakers bureaus | \checkmark | | | | | × | | |
| | | | | | | ADD | | |
| Payment for manuscript preparation | \checkmark | | | | | × | | |



| Relevant financial activities outs | side the | submit | ted work | | | |
|--|--------------|-------------------------|----------------------------------|-----------------------|----------|-----|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | |
| | | | | | | ADD |
| Patents (planned, pending or issued) | \checkmark | | | | | × |
| | | | | | | ADD |
| 9. Royalties | \checkmark | | | | | × |
| | | | | | | ADD |
| 10. Payment for development of educational presentations | \checkmark | | | | | × |
| | | | | | | ADD |
| 11. Stock/stock options | | \checkmark | | Eli Lilly and Company | | × |
| | | | | | | ADD |
| Travel/accommodations/ meeting expenses unrelated to activities listed** | \checkmark | | | | | × |
| | | | | | | ADD |
| 13. Other (err on the side of full disclosure) | \checkmark | | | | | × |
| | | | | | | ADD |

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section 4.

4. Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE



Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



| Section 1. | Identifying Inform | nation | | | |
|---|-------------------------------|-------------------|--|-----------------------|---|
| 1. Given Name (Fii Anita | rst Name) | 2. Surnan Kwan | ne (Last Name) | | 3. Effective Date (07-August-2008) 02-September-2010 |
| 4. Are you the corresponding author? Yes 🖌 No | | ✓ No | Corresponding Author's Name John Buse | | |
| 5. Manuscript Title Exenatide BID Us | e ie in Insulin-Treated Ty | pe 2 Diabe | tes: A Randomi | zed, Controlled Trial | |
| 6. Manuscript Ider | ntifying Number (if you kr | now it) | | | |

M10-1795

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

| The Work Under Consideration for Publication | | | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | | | |
| 1. Grant | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| 2. Consulting fee or honorarium | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| 3. Support for travel to meetings for the study or other purposes | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| 5. Payment for writing or reviewing the manuscript | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| Provision of writing assistance, medicines, equipment, or administrative support | ✓ | | | | | × | | | | |



| The Work Under Consideration for Publication | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | |
| | | | | | | ADD | | |
| 7. Other | \checkmark | | | | | × | | |
| | | | | | | ADD | | |

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

| Relevant financial activities outside the submitted work | | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------------------------------|-----|--|--|--|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | | | | |
| 1. Board membership | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 2. Consultancy | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 3. Employment | | \checkmark | | Lilly USA, LLC | I am employed by Lilly USA, LLC | × | | | |
| | | | | | | ADD | | | |
| 4. Expert testimony | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 5. Grants/grants pending | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| Payment for lectures including service on speakers bureaus | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 7. Payment for manuscript preparation | \checkmark | | | | | × | | | |



| Relevant financial activities outs | ide the | submit | ted work | | | |
|--|--------------|-------------------------|----------------------------------|--------|----------|-----|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | |
| | | | | | | ADD |
| Patents (planned, pending or issued) | \checkmark | | | | | × |
| | | | | | | ADD |
| 9. Royalties | \checkmark | | | | | × |
| | | | | | | ADD |
| 10. Payment for development of educational presentations | \checkmark | | | | | × |
| | | | | | | ADD |
| 11. Stock/stock options | \checkmark | | | | | × |
| | | | | | | ADD |
| Travel/accommodations/ meeting expenses unrelated to activities listed** | \checkmark | | | | | × |
| | | | | | | ADD |
| 13. Other (err on the side of full disclosure) | \checkmark | | | | | × |
| | | | | | | ADD |

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section 4.

Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE



Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



| Section 1. | Identifying Inform | ation | | | |
|--------------------------------|---|--------------------|----------------|--|--|
| 1. Given Name (Fir Michelle | rst Name) | 2. Surnan Lewis | ne (Last Name) | | 3. Effective Date (07-August-2008) 25-August-2010 |
| 4. Are you the corr | responding author? | Yes | ✓ No | Corresponding Author's Na John Buse | me |
| Controlled Trial | e ie in Insulin-Treated Ty ntifying Number (if you kn | | tes: A Randomi | zed, | |

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

| The Work Under Consideration for Publication | | | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | | | |
| 1. Grant | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| 2. Consulting fee or honorarium | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| 3. Support for travel to meetings for the study or other purposes | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| 5. Payment for writing or reviewing the manuscript | \checkmark | | | | | × | | | | |
| | | | | | | ADD | | | | |
| Provision of writing assistance, medicines, equipment, or administrative support | \checkmark | | | | | × | | | | |



| The Work Under Consideration for Publication | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | |
| | | | | | | ADD | | |
| 7. Other | \checkmark | | | | | × | | |
| | | | | | | ADD | | |

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

| Relevant financial activities out | side the | submit | ted work | | | |
|--|--------------|-------------------------|----------------------------------|-----------------------|---|-----|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | |
| 1. Board membership | \checkmark | | | | | × |
| | | | | | | ADD |
| 2. Consultancy | \checkmark | | | | | × |
| | | | | | | ADD |
| 3. Employment | | \checkmark | | Eli Lilly and Company | Met authorship criteria as an employee of Lilly | × |
| | | | | | | ADD |
| 4. Expert testimony | \checkmark | | | | | × |
| | | | | | | ADD |
| 5. Grants/grants pending | \checkmark | | | | | × |
| | | | | | | ADD |
| Payment for lectures including service on speakers bureaus | \checkmark | | | | | × |
| | | | | | | ADD |
| 7. Payment for manuscript preparation | \checkmark | | | | | × |



| Relevant financial activities outside the submitted work | | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|--------|----------|-----|--|--|--|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | | | | |
| | | | | | | ADD | | | |
| Patents (planned, pending or issued) | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 9. Royalties | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 10. Payment for development of educational presentations | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 11. Stock/stock options | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| Travel/accommodations/ meeting expenses unrelated to activities listed** | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 13. Other (err on the side of full disclosure) | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section 4.

Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE



Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



| Section 1. | Identifying Inforn | nation | | | | | | |
|---|----------------------------|---------------------|----------------------|--|--|--|--|--|
| 1. Given Name (Fii Byron | rst Name) | 2. Surnan Hoogwe | ne (Last Name) rf | | 3. Effective Date (07-August-2008) 03-November-2010 | | | |
| 4. Are you the cor | responding author? | Yes | ✓ No | Corresponding Author's Na John Buse | me | | | |
| 5. Manuscript Title Exenatide BID Use in Insulin-Treated Type 2 Diabetes: A Randomized, Controlled Trial | | | | | | | | |
| 6. Manuscript Ider | ntifying Number (if you kı | now it) | | | | | | |

M10-1795

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

| The Work Under Consideration for Publication | | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | | |
| 1. Grant | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 2. Consulting fee or honorarium | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 3. Support for travel to meetings for the study or other purposes | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 5. Payment for writing or reviewing the manuscript | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| Provision of writing assistance, medicines, equipment, or administrative support | \checkmark | | | | | × | | | |



| The Work Under Consideration for Publication | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | |
| | | | | | | ADD | | |
| 7. Other | \checkmark | | | | | × | | |
| | | | | | | ADD | | |

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

| Relevant financial activities out | side the | e submit | ted work | | | |
|--|--------------|-------------------------|----------------------------------|---|----------|-----|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | |
| 1. Board membership | \checkmark | | | | | × |
| | | | | | | ADD |
| 2. Consultancy | \checkmark | | | | | × |
| | | | | | | ADD |
| 3. Employment | | \checkmark | | Full time employee of Eli Lilly and Co | | × |
| | | | | | | ADD |
| 4. Expert testimony | \checkmark | | | | | × |
| | | | | | | ADD |
| 5. Grants/grants pending | \checkmark | | | | | × |
| | | | | | | ADD |
| Payment for lectures including service on speakers bureaus | \checkmark | | | | | × |
| | | | | | | ADD |
| 7. Payment for manuscript preparation | \checkmark | | | | | × |



| Relevant financial activities outs | side the | submit | ted work | | | |
|--|--------------|-------------------------|----------------------------------|--|----------|-----|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | |
| | | | | | | ADD |
| Patents (planned, pending or issued) | \checkmark | | | | | × |
| | | | | | | ADD |
| 9. Royalties | \checkmark | | | | | × |
| | | | | | | ADD |
| 10. Payment for development of educational presentations | \checkmark | | | | | × |
| | | | | | | ADD |
| 11. Stock/stock options | | \checkmark | | Eli Lilly stock (part of compensation package) | | × |
| | | | | | | ADD |
| Travel/accommodations/ meeting expenses unrelated to activities listed** | \checkmark | | | | | × |
| | | | | | | ADD |
| 13. Other (err on the side of full disclosure) | \checkmark | | | | | × |
| | | | | | | ADD |

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section 4. Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

 \checkmark No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

SAVE



Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.



Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. Identifying information.

Enter your full name. If you are NOT the corresponding author please check the box "no" and a space to enter the name of the corresponding author in the space that appears. Provide the requested manuscript information. Double-check the manuscript number and enter it.

2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes". Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

Other relationships.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.



| Section 1. | Identifying Inform | nation | | | | | | |
|--|----------------------------|-------------------------------------|---|--|--|--|--|--|
| 1. Given Name (Fi Julio | rst Name) | 2. Surname (Last Name Rosenstock |) | 3. Effective Date (07-August-2008) 15-November-2010 | | | | |
| 4. Are you the cor | responding author? | Yes 🖌 No | Corresponding Author's Na John B Buse MD PhD | ame | | | | |
| 5. Manuscript Title Use of Twice-Daily Exenatide in Basal Insulin–Treated Type 2 Diabetes A Randomized, Controlled Trial | | | | | | | | |
| 6. Manuscript Ider | ntifying Number (if you kr | now it) | | | | | | |

Section 2. The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

| The Work Under Consideration for Publication | | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|--|------------|-----|--|--|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | | | |
| 1. Grant | | | \checkmark | A research grant from Eli Lilly and Company to conduct the study | | × | | | |
| | | | | | | ADD | | | |
| 2. Consulting fee or honorarium | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 3. Support for travel to meetings for the study or other purposes | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 5. Payment for writing or reviewing the manuscript | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |



| The Work Under Consideration for Publication | | | | | | | |
|---|--------------|-------------------------|----------------------------------|----------------|------------|-----|--|
| Туре | No | Money Paid to You | Money to Your Institution* | Name of Entity | Comments** | | |
| 6. Provision of writing assistance, medicines, equipment, or administrative support | \checkmark | | | | | × | |
| | | | | | | ADD | |
| 7. Other | \checkmark | | | | | × | |
| | | | | | | ADD | |

* This means money that your institution received for your efforts on this study.

** Use this section to provide any needed explanation.

Section 3. Relevant financial activities outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were present during the 36 months prior to submission.

| Relevant financial activities outside the submitted work | | | | | | | | | |
|--|--------------|-------------------------|----------------------------------|---|----------|-----|--|--|--|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | | | | |
| 1. Board membership | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 2. Consultancy | | ✓ | | Pfizer, Roche, Sanofi- Aventis, Novo Nordisk, Eli Lilly, MannKind, GlaxoSmithKline, Takeda, Daiichi Sankyo, Forest, Johnson & Johnson, Novartis Boehringer Ingelheim, and Amylin. | | × | | | |
| | | | | | | ADD | | | |
| 3. Employment | \checkmark | | | | | × | | | |
| | | | | | | ADD | | | |
| 4. Expert testimony | \checkmark | | | | | × | | | |



| Relevant financial activities out | side the | submit | ted work | | | |
|--|--------------|-------------------------|----------------------------------|---|----------|-----|
| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your Institution* | Entity | Comments | |
| | | | | | | ADD |
| 5. Grants/grants pending | | | ✓ | Merck, Pfizer, Sanofi- Aventis, Novo Nordisk, Roche, Bristol-Myers Squibb, Eli Lilly, Forest, GlaxoSmithKline, Takeda, Novartis, AstraZeneca, Amylin, Johnson & Johnson, Daiichi Sankyo, MannKind, and Boehringer Ingelheim | | × |
| | | | | | | ADD |
| Payment for lectures including service on speakers bureaus | \checkmark | | | | | × |
| | | | | | | ADD |
| 7. Payment for manuscript preparation | \checkmark | | | | | × |
| | | | | | | ADD |
| 8. Patents (planned, pending or issued) | \checkmark | | | | | × |
| | | | | | | ADD |
| 9. Royalties | \checkmark | | | | | × |
| | | | | | | ADD |
| 10. Payment for development of educational presentations | \checkmark | | | | | × |
| | | | | | | ADD |
| 11. Stock/stock options | \checkmark | | | | | × |
| | | | | | | ADD |
| Travel/accommodations/ meeting expenses unrelated to activities listed** | \checkmark | | | | | × |
| | | | | | | ADD |
| 13. Other (err on the side of full disclosure) | \checkmark | | | | | × |
| | | | | | | |

* This means money that your institution received for your efforts.

** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.



Section 4. Other relationships

Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

✓ No other relationships/conditions/circumstances that present a potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Hide All Table Rows Checked 'No'

| S | A | V | | |
|---|---|---|--|--|

Evaluation and Feedback

Please visit <u>http://www.icmje.org/cgi-bin/feedback</u> to provide feedback on your experience with completing this form.



INSTRUCTIONS:

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form has five parts.

1. Identifying information.

Each author should submit a separate form. Provide complete information and double-check the manuscript number. If you are NOT the corresponding author please insert his or her name.

2. The work under consideration for publication.

Please provide information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The idea is to provide for the reader information about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. If you check the "No" box it means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds to pay you. If you or your institution did receive funds from a third party to support the work, check "Yes" along with the appropriate boxes to indicate the type of support and whether you or your institution received it.

3. Relevant financial activities outside the submitted work.

Please report all sources of revenue relevant to the submitted work that accrued either directly to you or were paid to your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. If there is any question, it is usually better to disclose a relationship than not to do so. Please note that your interactions with the work's sponsor outside the submitted work should be listed here. For each category list each entity on a separate line. Use as many lines as necessary to provide complete information. In addition, please disclose relationships that fall outside the 36-month window that readers may want to know about and could reasonably criticize you for not disclosing (for example, long-term financial relationships that are now ended).

The goal of this section is to provide information for our reviewers and readers about your interactions with entities in the biomedical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer. For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to benefit financially from the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as the NIH or the MRC, need not be disclosed. For example, if the NIH sponsored a piece of work you have been involved in but drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. Financial relationships involving your spouse or partner or your children (under 18 years of age).

If monies from the types of relationships listed in Section 3 were paid to your spouse or partner or dependent children, please list the type of activity and source of the money.

5. Nonfinancial associations.

Please report any personal, professional, political, institutional, religious, or other associations that a reasonable reader would want to know about in relation to the submitted work.



Section 1. Identifying Information.

| Given Name: (or first) | Richard | Surname: (or last) | Bergenstal | | 17-November-2010 | | | | | |
|--|------------------------------|-----------------------|---------------------------------|---------------------|------------------|--|--|--|--|--|
| Are you the corresponding author? Yes No Format example: 07-August-2 | | | | | | | | | | |
| Corresponding | Corresponding author's name: | | | | | | | | | |
| | | | | | | | | | | |
| Manuscript T | itle: Exenatide BID Use in | Insulin-Treated | d Type 2 Diabetes: A Randomized | d, Controlled Trial | | | | | | |
| Manuscript Id | lentifying Number (if y | ou know it): | | | | | | | | |

Section 2. Information about the support of the work under consideration for publication.

Did you or your institution at any time receive payment or support in kind for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc...)?

No No

Yes, specify nature of compensation

If you have more than one relationship, click "Add +" to add a row. Click "Del ×" to delete an extra row.

| Туре | Money Paid to You* | | | | Name of Entity | Comments** | |
|--|-----------------------|-----|----|-----------|----------------|---------------------|---------------------|
| | No | Yes | No | Yes | | | |
| Grant | \square | | | \square | Lilly | Clinical Study Site | $\text{Del} \times$ |
| | | • | | | • | | Add + |
| Consulting fee or honorarium | | | | | | | Del × |
| | | | | | | | Add + |
| Support for travel to meetings for the study or otherwise | | | | | | | Del × |
| | | | | | | | Add + |
| Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like | | | | | | | Del × |
| | | | | | | | Add + |
| Payment for writing or reviewing the manuscript | | | | | | | Del × |



| Туре | Money Paid to You* | | Paid Du* Money to Your Institution | | Name of Entity | Comments** | |
|--|-----------------------|--|--|--|----------------|------------|-------|
| | | | | | | | Add + |
| Support in kind such as writing, provision of medicines or equipment, or administrative support | | | \boxtimes | | | | Del × |
| | | | | | | | Add + |
| Other | \square | | \boxtimes | | | | Del × |
| | | | | | | • | Add + |

**Use this section to provide any needed explanation

Section 3. Information about relevant financial relationships outside the submitted work.

Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with any entities that have an interest related to the submitted work. Use one line for each entity; add as many lines as you need. Use the comments column to indicate any additional information that you think a reader or editor would want to know about the compensation. Report relationships that were present during the 36 months prior to submission. In addition please disclose relationships that fall outside the 36-month window that readers may want to know about and could reasonably criticize you for not disclosing (for example, long-term financial relationships that are now ended).

If you have more than one relationship, click "Add +" to add a row. Click "Del ×" to delete an extra row.

| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your institution | Entity | Comments | |
|---|-------------|-------------------------|---------------------------------|----------------------|----------|---------------------|
| Board membership | \boxtimes | | | | | Del × |
| | | 1 | 1 | I | | Add + |
| Consultancy | | | \square | Abbott Diabetes Care | | Del × |
| Consultancy | | | | Amylin | | $\text{Del} \times$ |
| Consultancy | | | | Bayer | | $\text{Del} \times$ |
| Consultancy | | | | Calibra | | $\text{Del} \times$ |
| Consultancy | | | | Eli Lilly | | $\text{Del} \times$ |
| Consultancy | | | | Intarcia | | $\text{Del} \times$ |
| Consultancy | | | | Mannkind | | $\text{Del} \times$ |
| Consultancy | | | | Medtronic | | $\text{Del} \times$ |
| Consultancy | | | | Novo Nordisk | | Del × |
| Consultancy | | | \square | Pfizer | | Del × |



| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your institution | Entity | Comments | |
|---|-------------|-------------------------|---------------------------------|----------------------|----------|---------------------|
| Consultancy | | | | ResMed | | Del × |
| Consultancy | | | | Roche | | Del × |
| Consultancy | | | \square | sanofi aventis | | Del × |
| Consultancy | | | \square | Takeda | | Del × |
| | | | | | | Add + |
| Employment | \boxtimes | | | | | Del × |
| | | | | | , | Add + |
| Expert testimony | \boxtimes | | | | | $\text{Del} \times$ |
| | | I | 1 | | 1 | Add + |
| Gifts | \boxtimes | | | | | $\text{Del} \times$ |
| | | | 1 | | , | Add + |
| Grants/grants pending | | | | | | Del × |
| Grants/grants pending | | | | Abbott Diabetes Care | | Del × |
| Grants/grants pending | | | | Biodel | | Del × |
| Grants/grants pending | | | | Calibra | | Del × |
| Grants/grants pending | | | | Eli Lilly | | Del × |
| Grants/grants pending | | | \square | Hygieia | | Del × |
| Grants/grants pending | | | \square | Intuity | | Del × |
| Grants/grants pending | | | \square | LifeScan | | Del × |
| Grants/grants pending | | | \square | Medtronic | | Del × |
| Grants/grants pending | | | \square | Novo Nordisk | | Del × |
| Grants/grants pending | | | \square | Pfizer | | Del × |
| Grants/grants pending | | | \square | Resmed | | Del × |
| Grants/grants pending | | | | Roche | | Del × |
| Grants/grants pending | | | | sanofi aventis | | Del × |
| Grants/grants pending | | | | Takeda | | Del × |
| Grants/grants pending | | | | United Health Group | | Del × |
| Grants/grants pending | | | | Valeritas | | Del × |
| | | | | | | Add + |



| Type of Relationship (in alphabetical order) | No | Money Paid to You | Money to Your institution | Entity | Comments | |
|--|-------------|-------------------------|---------------------------------|---|---|---------------------|
| Honoraria | | | | Companies listed under Consultancies | The International Diabetes Center has received honorairia from companies on behalf of Dr. Bergenstal for his consulting services | Del × |
| | | | | | | Add + |
| Payment for manuscript preparation | \boxtimes | | | | | Del × |
| | | | | | | Add + |
| Patents (planned, pending or issued) | \boxtimes | | | | | $\text{Del} \times$ |
| | | | | | | Add + |
| Royalties | | | | Betty Crocker Diabetes Cookbook | co-author | Del × |
| | | | | | | Add + |
| Payment for development of educational presentations including service on speakers' bureaus | \boxtimes | | | | | Del × |
| | | • | | | | Add + |
| Stock/stock options | | | | Merck | family inheritance | Del × |
| | | 1 | | | | Add + |
| Travel/accommodations expenses covered or reimbursed | | | | Companies listed under Consultancies and Grants/ Grants Pending | The International Diabetes Center has received reimbursement for travel and accommodations from companies on behalf of Dr. Bergenstal for his consulting services and grant-related research | Del × |
| | | | | | 1 | Add + |
| Other (err on the side of full disclosure) | \boxtimes | | | | | Del × |
| | | | | • | | Add + |



Section 4. Information about financial relationships involving your spouse or partner or your children (under 18 years of age).

Do your children or your spouse or partner have financial relationships with entities that have an interest in the content of the submitted work?

No other relationships/conditions/circumstances that present potential conflict of interest

Yes, the following relationships/conditions/circumstances are present (explain below):

Section 5. Information about relevant nonfinancial associations.

Do you have any relevant nonfinancial associations or interests (personal, professional, political, institutional, religious, or other) that a reasonable reader would want to know about in relation to the submitted work?

No relevant nonfinancial relationships/conditions/circumstances to report.

Yes, the following relevant nonfinancial relationships/conditions/circumstances are present (explain below):

At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.

Save Form